## DAFTAR PUSTAKA


1. NICE. Non-alcoholic fatty liver disease: Assessment and management. Vol. 18, Current Gastroenterology Reports. 2016.
2. Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S. Buku Ajar Ilmu Penyakit Dalam Jilid II edisi VI. Jakarta: Interna Publishing; 2015.
3. Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic Fatty Liver Disease: A Clinical Update. J Clin Transl Hepatol [Internet]. 2017; Available from: http://www.xiahepublishing.com/ArticleFullText.aspx?sid=2&jid=1&id=10.14218%2FJCTH.2017.00013
4. Ray K. NAFLD—the next global epidemic. Nat Rev Gastroenterol Hepatol [Internet]. 2013;10(11):621. Available from: https://doi.org/10.1038/nrgastro.2013.197
5. Calzadilla Bertot L, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci [Internet]. 2016 May 20;17(5):774. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27213358
6. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865–73.
7. Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence based treatment. World J Gastroenterol [Internet]. 2014 May 14;20(18):5442–60. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24833875
8. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol. 2009;24(2):248–54.
9. Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012.
10. Mahale AR, Prabhu SD, Nachiappan M, Fernandes M, Ullal S. Clinical relevance of reporting fatty liver on ultrasound in asymptomatic patients during routine health checkups. J Int Med Res [Internet]. 2018/09/05. 2018 Nov;46(11):4447–54. Available from: https://www.ncbi.nlm.nih.gov/pubme

d/30185098

11. Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis 2016; 20: 205-214.
12. Fan JG, Kim SU, Wong VWS. New trends on obesity and NAFLD in Asia. J Hepatol [Internet]. 2017;67(4):862–73. Available from: http://dx.doi.org/10.1016/j.jhep.2017.06.003
13. Benedict M, Zhang X, Benedict M, Zhang X. Non-alcoholic fatty liver disease : An expanded review. 2017;9(16):715–32.
14. Hashimoto E, Tokushige K, Ludwig J. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. 2014;1–9.
15. Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, Cortez-Pinto H, Grieco A, Machado MV, Miele L, Targher G. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis 2015; 47: 997-100.
16. Kalia HS, Gaglio PJ. The Prevalence and Pathobiology of Nonalcoholic Fatty Liver Disease in Patients of Different Races or Ethnicities. Clin Liver Dis 2016; 20: 215-224.
17. Satapathy SK, Sanyal AJ. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2015; 35: 221-235.
18. Andersen CJ, Fernandez ML. Dietary strategies to reduce metabolic syndrome. Rev Endocr Metab Disord 2013; 14: 241-254.
19. Godos J, Federico A, Dallio M, Scazzina F. Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection. Int J Food Sci Nutr 2017; 68: 18-27.
20. Carnethon MR, Fortmann SP, Palaniappan L, Duncan BB, Schmidt MI, Chambless LE. Risk factors for progression to incident hyperinsulinemia: the Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol 2003; 158: 1058-1067.
21. Hamabe A, Uto H, Imamura Y, Kusano K, Mawatari S, Kumagai K, et al. Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over

a 10-year period. J Gastroenterol 2011; 46: 769-778.

22. Macut D, Tziomalos K, Božić-Antić I, Bjekić-Macut J, Katsikis I, Papadakis E, et al. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod [Internet]. 2016 Apr 12;31(6):1347–53. Available from: https://doi.org/10.1093/humrep/dew076

23. Kahal H, Abouda G, Rigby AS, Coady AM, Kilpatrick ES, Atkin SL. Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) [Internet]. 2014;81(4):523–8. Available from: https://doi.org/10.1111/cen.12369

24. Paschetta E, Belci P, Alisi A, Liccardo D, Cutrera R, Musso G, Nobili V. OSAS-related inflammatory mechanisms of liver injury in nonalcoholic fatty liver disease. Mediators Inflamm 2015; 2015: 815721.

25. Polotsky VY, Patil SP, Savransky V, Laffan A, Fonti S, Frame LA, Steele KE, et al. Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity. Am J Respir Crit Care Med 2009; 179: 228-234.

26. Teff KL, Elliott SS, Tschöp M, Kieffer TJ, Rader D, Heiman M, et al. Dietary Fructose Reduces Circulating Insulin and Leptin, Attenuates Postprandial Suppression of Ghrelin, and Increases Triglycerides in Women. J Clin Endocrinol Metab [Internet]. 2004 Jun 1;89(6):2963–72. Available from: https://doi.org/10.1210/jc.2003-031855

27. Carr RM, Oranu A, Khungar V. HHS Public Access. 2017;45(4):639–52.

28. Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A. Gut microbiota and metabolic syndrome. World journal of gastroenterology. 2014; 20:16079–16094.

29. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the united states: Impact of ethnicity. Hepatology. 2004; 40:1387–1395.

30. Petersen KF, Dufour S, Feng J, Befroy D, Dziura J, Dalla Man C, Cobelli C, Shulman GI. Increased prevalence of insulin resistance and nonalcoholic

fatty liver disease in asian-indian men. Proc Natl Acad Sci U S A. 2006; 103:18273–18277.

31. Dongiovanni P, Romeo S, Valenti L. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. 2015;2015(Vldl):1–10.
32. Fu Z, Gilbert ER, Liu D. Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes. Curr Diabetes Rev. 2013; 9:25–53.
33. Manco M. Insulin Resistance and NAFLD: A Dangerous Liaison beyond the Genetics. Children. 2017;4(8):74.
34. Lieberman MA. Marks ' Basic Medical Biochemistry : A Clinical Approach , 2nd Edition Marks ' Basic Medical Biochemistry : A Clinical Approach , 2nd Edition. 2005.
35. Iii ATP, Quick GA, Reference D. ATP III Guidelines At-A-Glance Quick Desk Reference.
36. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ [Internet]. 2007 Apr 10;176(8):1113–20. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17420495
37. Barter PJ, Rye KA. Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism? Circulation 2006;113:1553-5.
38. Carlson LA. Nicotinic acid: The broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005;258(2):94–114.
39. Purnell JQ. Definitions, Classification, and Epidemiology of Obesity. [Updated 2018 Apr 12]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.
40. Nishida C, Barba C, Cavalli-Sforza T, Cutter J, Deurenberg P, Darnton-Hill I, et al. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–63.
41. WHO. Waist Circumference and Waist-Hip Ratio. In: Report of a WHO ExpertConsultation.Geneva;2008.
42. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism

[Internet]. 2019;92:6–10. Available from: https://doi.org/10.1016/j.metabol.2018.09.005

43. Harbuwono DS, Pramono LA, Yunir E, Subekti I. Obesity and central obesity in Indonesia: evidence from a national health survey. Med J Indones [Internet]. 2018Sep.9 [cited 2019Nov.18];27(2):114-20. Available from: https://mji.ui.ac.id/journal/index.php/mji.
44. Kementrian Kesehatan RI. Hasil Utama Laporan Riskesdas 2018. Jakarta Badan Penelit dan Pengemb Kesehat Dep Kesehat Republik Indones. 2018;22.
45. Departemen Kesehatan. Riset Kesehatan Dasar [Internet]. 2017 [cited 2018 Sep 30]. Available from: http://terbitan.litbang.depkes.go.id/penerbitan/index.php/lpb/catalog/downl oad/22/22/29-2.
46. Sherwood L. Fisiologi Manusia dari Sel ke Sistem. 6th ed. Jakarta: EGC; 2012.708-710p.
47. Jeffrey A. Stronger Relationship Between Central Adiposity And C ReactiveProteinInOlderWomen.2009;16:84–9.
48. Panuganti KK, Gossman WG. Obesity. [Updated 2019 May 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459357/.
49. Lutz HT, Gebhard M, Byung. Manual of diagnostic ultrasound. World Heal Organ. 2011;1(2):139–67.
50. Singh D, Das CJ, Baruah MP. Imaging of non alcoholic fatty liver disease: A road less travelled. Indian J Endocrinol Metab. 2013 Nov;17(6):990–5.
51. Smith J. EFSUMB Course Book on Ultrasound. Ultrasound Med Biol [Internet]. 2013 Jun 1;39(6):1128. Available from: https://doi.org/10.1016/j.ultrasmedbio.2012.10.006
52. Toshikuni N, Tsutsumi M, Arisawa T. Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. World J Gastroenterol [Internet]. 2014 Jul 14;20(26):8393–406. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25024597
53. Khov N, Sharma A, Riley TR. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol [Internet]. 2014 Jun

14;20(22):6821–5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24944472

54. Ko H, Yoshida EM. Acute fatty liver of pregnancy. Can J Gastroenterol [Internet]. 2006 Jan;20(1):25–30. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16432556

55. Rabinowich L, Shibolet O. Drug induced steatohepatitis: An uncommon culprit of a common disease. Biomed Res Int. 2015;2015.

56. Supranto J. Teknik Sampling Untuk Survei dan Eksperimen. Jakarta: Rineka Cipta; 2000.

57. Allen AM, Therneau TM, Larson JJ, Coward A, Somers VK, Kamath PS. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology [Internet]. 2018/03/23. 2018 May;67(5):1726–36.

58. Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol [Internet]. 2017 Dec 21;23(47):8263–76. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29307986

59. Veronica G, Esther R-RM. Aging, metabolic syndrome and the heart. Aging Dis [Internet]. 2012/03/13. 2012 Jun;3(3):269–79.

60. Summart U, Thinkhamrop B, Chamadol N, Khuntikeo N, Songthamwat M, Kim CS. Gender differences in the prevalence of nonalcoholic fatty liver disease in the Northeast of Thailand: A population-based cross-sectional study. F1000Research [Internet]. 2017 Sep 4;6:1630. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29093809

61. Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol [Internet]. 2012 Jan 21;18(3):237–43. Available from: https://pubmed.ncbi.nlm.nih.gov/22294826

62. Wong VW-S, Chu WC-W, Wong GL-H, Chan RS-M, Chim AM-L, Ong A, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut [Internet]. 2012 Mar

1;61(3):409 LP – 415. Available from: http://gut.bmj.com/content/61/3/409.abstract

63. Khabazkhoob M, Emamian MH, Hashemi H, Shariati M, Fotouhi A. Prevalence of Overweight and Obesity in the Middle-age Population: A Priority for the Health System. Iran J Public Health [Internet]. 2017 Jun;46(6):827–34. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28828326

64. Astari NA, Decroli E, Yerizel E. Gambaran NAFLD pada Pasien dengan Sindrom Metabolik di Poliklinik Penyakit Dalam RSUP Dr. M. Djamil Padang. J Kesehat Andalas. 2015;4(2):441–6.

65. Liu X, Yu S, Mao Z, Li Y, Zhang H, Yang K, et al. Dyslipidemia prevalence, awareness, treatment, control, and risk factors in Chinese rural population: the Henan rural cohort study. Lipids Health Dis [Internet]. 2018 May 22;17(1):119. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29788966

66. Gemilang B, Yanwirasti, Miro S. Hubungan Kadar Trigliserida dan Kolesterol-HDL Terhadap Kadar Alanine Aminotransferase pada Pasien Non Alcoholic Fatty Liver Disease. J Kesehat Andalas [Internet]. 2016;5(1):179–84. Available from: http://download.portalgaruda.org/article.php?article=421620&val=7288&title=Hubungan Kadar Trigliserida dan Kolesterol-HDL Terhadap Kadar Alanine Aminotransferase pada Pasien Non Alcoholic Fatty Liver Disease

67. Buss J. Limitations of Body Mass Index to Assess Body Fat. Workplace Health Saf. 2014;62(6):264–264.

68. Pang Q, Zhang JY, Qu K, Song SD, Liu SS, Liu C. Central obesity induces a greater risk of hepatocellular carcinoma than general obesity. Hepatology [Internet]. 2015 Sep 1;62(3):979–80. Available from: https://doi.org/10.1002/hep.27668

69. Tomizawa M, Kawanabe Y, Shinozaki F, Sato S, Motoyoshi Y, Sugiyama T, et al. Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. Biomed Reports. 2014;2(5):633–6.